SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

European Journal of Endocrinology

Volumn 178, Issue 4, 2018, Pages R113-R125

  Esterline, Russell L ^a   Vaag, Allan ^b   Oscarsson, Jan ^a   Vora, Jiten ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUCAGON; GLUCOSE; GLYCOGEN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; MTOR PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; TARGET OF RAPAMYCIN KINASE;

AUTOPHAGY; BIOGENESIS; CELL ORGANELLE; CIRCADIAN RHYTHM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EATING; GLUCONEOGENESIS; HUMAN; LIVER; LYSOSOME; METABOLISM; MTOR SIGNALING; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ANIMALS; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DISEASES; SODIUM-GLUCOSE TRANSPORTER 2; TOR SERINE-THREONINE KINASES;

EID: 85044723157     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-17-0832     Document Type: Review

References (84)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 2015 373 2117-2128. (https://doi. org/10.1056/NEJMoa1504720)
2. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC & Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine 2016 375 323-334. (https://doi. org/10.1056/NEJMoa1515920)
3. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M & Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine 2017 377 644-657. (https://doi.org/10.1056/ NEJMoa1611925)
4. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen M, Thuresson M et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation 2017 136 249-259. (https://doi.org/10.1161/ circulationaha.117.029190)
5. Abdul-Ghani M, Del Prato S, Chilton R & DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 2016 39 717-725. (https://doi. org/10.2337/dc16-0041)
6. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC & Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research 2015 12 90-100. (https://doi.org/10.1177/1479164114559852)
7. Sattar N, McLaren J, Kristensen SL, Preiss D & McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016 59 1333-1339. (https://doi.org/10.1007/s00125-016-3956-x)
8. McMurray J. EMPA-REG - the 'diuretic hypothesis'. Journal of Diabetes and its Complications 2016 30 3-4. (https://doi.org/10.1016/j. jdiacomp.2015.10.012)
9. DeFronzo RA. The EMPA-REG study: what has it told us? A diabetologist's perspective. Journal of Diabetes and its Complications 2016 30 1-2. (https://doi.org/10.1016/j.jdiacomp.2015.10.013)
10. Jorgensen NB, Pedersen J & Vaag AA. EMPA-REG: glucose excretion and lipid mobilization - not storage - saves lives. Journal of Diabetes and its Complications 2016 30 753. (https://doi.org/10.1016/j. jdiacomp.2016.02.015)
11. Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L & Abdul-Ghani M. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 2016 39 2036-2041. (https://doi.org/10.2337/dc15- 2688)
12. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR & Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016 65 1190-1195. (https://doi.org/10.2337/db15-1356)
13. Ferrannini E, Mark M & Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a 'thrifty substrate' hypothesis. Diabetes Care 2016 39 1108-1114. (https://doi.org/10.2337/dc16-0330)
14. Mudaliar S, Alloju S & Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016 39 1115-1122. (https://doi.org/10.2337/dc16-0542)
15. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N & List J. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technology and Therapeutics 2014 16 137-144. (https://doi.org/10.1089/dia.2013.0167)
16. Storlien L, Oakes ND & Kelley DE. Metabolic flexibility. Proceedings of the Nutrition Society 2004 63 363-368. (https://doi.org/10.1079/ PNS2004349)
17. Kelley DE, Goodpaster B, Wing RR & Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. American Journal of Physiology 1999 277 E1130-E1141. (https://doi.org/10.1152/ajpcell.1999.277.6.C1130)
18. Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell 2014 159 1253-1262. (https://doi. org/10.1016/j.cell.2014.11.034)
19. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. Journal of Clinical Investigation 2014 124 509-514. (https://doi.org/10.1172/JCI70704)
20. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J & Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Journal of Clinical Endocrinology and Metabolism 2012 97 1020-1031. (https://doi.org/10.1210/jc.2011- 2260)
21. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J & Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism 2014 16 159-169. (https://doi.org/10.1111/dom.12189)
22. Berg JM, Tymoczko JL & Stryer L. Section 30, the integration of metabolism. In Biochemistry, 5 ed., ch 30, pp 1250-1280. New York: W H Freeman, 2002.
23. Longo VD & Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metabolism 2014 19 181-192. (https://doi. org/10.1016/j.cmet.2013.12.008)
24. Laplante M & Sabatini DM. mTOR signaling in growth control and disease. Cell 2012 149 274-293. (https://doi.org/10.1016/j. cell.2012.03.017)
25. Lee J, Giordano S & Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochemical Journal 2012 441 523-540. (https://doi.org/10.1042/BJ20111451)
26. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes, Obesity and Metabolism 2011 13 (Supplement 1) 126-132. (https://doi.org/10.1111/j.1463-1326.2011.01449.x)
27. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC & Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011 54 2506-2514. (https://doi. org/10.1007/s00125-011-2204-7)
28. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, Chasan-Taber L, Albright AL & Braun B. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care 2010 33 2692-2696. (https://doi. org/10.2337/dc10-1548)
29. Jorgensen NB, Dirksen C, Bojsen-Moller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S & Holst JJ. Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013 62 3044-3052. (https://doi.org/10.2337/db13-0022)
30. Longo VD & Panda S. Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metabolism 2016 23 1048-1059. (https://doi.org/10.1016/j.cmet.2016.06.001)
31. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. Journal of Clinical Investigation 2005 115 1699-1702. (https://doi.org/10.1172/JCI25758)
32. Laplante M & Sabatini DM. mTOR signaling at a glance. Journal of Cell Science 2009 122 3589-3594. (https://doi.org/10.1242/ jcs.051011)
33. Kume S, Koya D, Uzu T & Maegawa H. Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy. BioMed Research International 2014 2014 315494. (https://doi. org/10.1155/2014/315494)
34. Zoncu R, Efeyan A & Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology 2011 12 21-35. (https://doi.org/10.1038/nrm3025)
35. Russell RC, Yuan HX & Guan KL. Autophagy regulation by nutrient signaling. Cell Research 2014 24 42-57. (https://doi.org/10.1038/ cr.2013.166)
36. Korolchuk VI, Saiki S, Lichtenberg M, Siddiqi FH, Roberts EA, Imarisio S, Jahreiss L, Sarkar S, Futter M, Menzies FM et al. Lysosomal positioning coordinates cellular nutrient responses. Nature Cell Biology 2011 13 453-460. (https://doi.org/10.1038/ncb2204)
37. Zhou J, Tan SH, Nicolas V, Bauvy C, Yang ND, Zhang J, Xue Y, Codogno P & Shen HM. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Research 2013 23 508-523. (https://doi. org/10.1038/cr.2013.11)
38. Sandri M. FOXOphagy path to inducing stress resistance and cell survival. Nature Cell Biology 2012 14 786-788. (https://doi. org/10.1038/ncb2550)
39. Webster BR, Scott I, Traba J, Han K & Sack MN. Regulation of autophagy and mitophagy by nutrient availability and acetylation. Biochimica et Biophysica Acta 2014 1841 525-534. (https://doi. org/10.1016/j.bbalip.2014.02.001)
40. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO Journal 2008 27 433-446. (https://doi.org/10.1038/ sj.emboj.7601963)
41. Ding WX & Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biological Chemistry 2012 393 547-564. (https:// doi.org/10.1515/hsz-2012-0119)
42. Liesa M & Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metabolism 2013 17 491-506. (https://doi.org/10.1016/j.cmet.2013.03.002)
43. Terman A, Kurz T, Navratil M, Arriaga EA & Brunk UT. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. Antioxidants and Redox Signaling 2010 12 503-535. (https://doi.org/10.1089/ ars.2009.2598)
44. Gomes LC, Di Benedetto G & Scorrano L. Essential amino acids and glutamine regulate induction of mitochondrial elongation during autophagy. Cell Cycle 2011 10 2635-2639. (https://doi.org/10.4161/ cc.10.16.17002)
45. Meijer AJ & Codogno P. Autophagy: regulation and role in disease. Critical Reviews in Clinical Laboratory Sciences 2009 46 210-240. (https://doi.org/10.1080/10408360903044068)
46. Song M, Mihara K, Chen Y, Scorrano L & Dorn GW 2nd. Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metabolism 2015 21 273-285. (https://doi.org/10.1016/j. cmet.2014.12.011)
47. Gonzalez CD, Lee MS, Marchetti P, Pietropaolo M, Towns R, Vaccaro MI, Watada H & Wiley JW. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 2011 7 2-11. (https://doi.org/10.4161/auto.7.1.13044)
48. Las G & Shirihai OS. The role of autophagy in beta-cell lipotoxicity and type 2 diabetes. Diabetes, Obesity and Metabolism 2010 12 (Supplement 2) 15-19. (https://doi.org/10.1111/j.1463- 1326.2010.01268.x)
49. Marrif HI & Al-Sunousi SI. Pancreatic beta cell mass death. Frontiers in Pharmacology 2016 7 83. (https://doi.org/10.3389/fphar.2016.00083)
50. Tanaka Y, Kume S, Kitada M, Kanasaki K, Uzu T, Maegawa H & Koya D. Autophagy as a therapeutic target in diabetic nephropathy. Experimental Diabetes Research 2012 2012 628978. (https://doi. org/10.1155/2012/628978)
51. De Meyer GR, De Keulenaer GW & Martinet W. Role of autophagy in heart failure associated with aging. Heart Failure Reviews 2010 15 423-430. (https://doi.org/10.1007/s10741-010-9166-6)
52. Levine B & Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008 132 27-42. (https://doi.org/10.1016/j.cell.2007.12.018)
53. Montgomery MK & Turner N. Mitochondrial dysfunction and insulin resistance: an update. Endocrine Connections 2015 4 R1-R15. (https:// doi.org/10.1530/EC-14-0092)
54. Yoon Y, Galloway CA, Jhun BS & Yu T. Mitochondrial dynamics in diabetes. Antioxidants and Redox Signaling 2011 14 439-457. (https:// doi.org/10.1089/ars.2010.3286)
55. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD, Hegardt FG & Muoio DM. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. Journal of Biological Chemistry 2009 284 22840-22852. (https://doi.org/10.1074/jbc. M109.032888)
56. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, Kheterpal I, Zhang J et al. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metabolism 2012 15 764-777. (https:// doi.org/10.1016/j.cmet.2012.04.005)
57. Lindeboom L, Nabuurs CI, Hoeks J, Brouwers B, Phielix E, Kooi ME, Hesselink MK, Wildberger JE, Stevens RD, Koves T et al. Long-echo time MR spectroscopy for skeletal muscle acetylcarnitine detection. Journal of Clinical Investigation 2014 124 4915-4925. (https://doi. org/10.1172/JCI74830)
58. Edwards JL, Quattrini A, Lentz SI, Figueroa-Romero C, Cerri F, Backus C, Hong Y & Feldman EL. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia 2010 53 160-169. (https://doi.org/10.1007/s00125-009-1553-y)
59. Vincent AM, Edwards JL, McLean LL, Hong Y, Cerri F, Lopez I, Quattrini A & Feldman EL. Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathologica 2010 120 477-489. (https://doi.org/10.1007/s00401- 010-0697-7)
60. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, Chang CR & Tsai YS. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Molecular and Cellular Biology 2012 32 309-319. (https://doi.org/10.1128/ MCB.05603-11)
61. Perier C & Vila M. Mitochondrial biology and Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2012 2 a009332. (https:// doi.org/10.1101/cshperspect.a009332)
62. Ramsay RR, Kowal AT, Johnson MK, Salach JI & Singer TP. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Archives of Biochemistry and Biophysics 1987 259 645-649. (https://doi.org/10.1016/0003- 9861(87)90531-5)
63. Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, Harvey R, Davies SE, Allison M, Coleman N & Alexander G. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. Journal of Hepatology 2013 58 549-556. (https:// doi.org/10.1016/j.jhep.2012.10.031)
64. Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoefel WT et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metabolism 2015 21 739-746. (https://doi.org/10.1016/j.cmet.2015.04.004)
65. Chen H & Chan DC. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Human Molecular Genetics 2009 18 R169-R176. (https://doi.org/10.1093/ hmg/ddp326)
66. Huber TB, Edelstein CL, Hartleben B, Inoki K, Jiang M, Koya D, Kume S, Lieberthal W, Pallet N, Quiroga A et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 2012 8 1009-1031. (https://doi.org/10.4161/auto.19821)
67. Higgins GC & Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? British Journal of Pharmacology 2014 171 1917-1942. (https://doi. org/10.1111/bph.12503)
68. Kobayashi S & Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochimica et Biophysica Acta 2015 1852 252-261. (https://doi.org/10.1016/j.bbadis.2014.05.020)
69. Liang Q & Kobayashi S. Mitochondrial quality control in the diabetic heart. Journal of Molecular and Cellular Cardiology 2016 95 57-69. (https://doi.org/10.1016/j.yjmcc.2015.12.025)
70. Hoeks J, van Herpen NA, Mensink M, Moonen-Kornips E, van Beurden D, Hesselink MK & Schrauwen P. Prolonged fasting identifies skeletal muscle mitochondrial dysfunction as consequence rather than cause of human insulin resistance. Diabetes 2010 59 2117-2125. (https://doi.org/10.2337/db10-0519)
71. Tuominen JA, Ebeling P, Bourey R, Koranyi L, Lamminen A, Rapola J, Sane T, Vuorinen-Markkola H & Koivisto VA. Postmarathon paradox: insulin resistance in the face of glycogen depletion. American Journal of Physiology 1996 270 E336-E343. (https://doi.org/10.1152/ ajpendo.1996.270.2.E336)
72. Rambold AS, Cohen S & Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Developmental Cell 2015 32 678-692. (https://doi.org/10.1016/j.devcel.2015.01.029)
73. Solloway MJ, Madjidi A, Gu C, Eastham-Anderson J, Clarke HJ, Kljavin N, Zavala-Solorio J, Kates L, Friedman B, Brauer M et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass. Cell Reports 2015 12 495-510. (https://doi.org/10.1016/j.celrep.2015.06.034)
74. Johnston O, Rose CL, Webster AC & Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Journal of the American Society of Nephrology: JASN 2008 19 1411-1418. (https://doi. org/10.1681/ASN.2007111202)
75. Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Therapeutic Advances in Endocrinology and Metabolism 2016 7 110-127. (https://doi. org/10.1177/2042018816641580)
76. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. British Journal of Pharmacology 2012 165 2325-2340. (https://doi.org/10.1111/j.1476- 5381.2011.01716.x)
77. Savendahl L & Underwood LE. Fasting increases serum total cholesterol, LDL cholesterol and apolipoprotein B in healthy, nonobese humans. Journal of Nutrition 1999 129 2005-2008. (https:// doi.org/10.1093/jn/129.11.2005)
78. Spinar J & Smahelova A. SAVOR TIMI 53 - saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Vnitrni Lekarstvi 2013 59 1003-1007.
79. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, Thorp E, Accili D, Horton JD & Tall AR. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. Journal of Clinical Investigation 2012 122 1262-1270. (https://doi.org/10.1172/JCI61919)
80. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nature Medicine 2015 21 512-517. (https://doi.org/10.1038/nm.3828)
81. Canto C & Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacological Reviews 2012 64 166-187. (https://doi.org/10.1124/pr.110.003905)
82. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, Mark M & Sulpice T. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes 2016 65 2032-2038. (https://doi. org/10.2337/db16-0049)
83. Siess EA, Kientsch-Engel RI & Wieland OH. Role of free oxaloacetate in ketogenesis. Derivation from the direct measurement of mitochondrial [3-hydroxybutyrate]/[acetoacetate] ratio in hepatocytes. European Journal of Biochemistry 1982 121 493-499. (https://doi.org/10.1111/j.1432-1033.1982.tb05814.x)
84. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, Thoren F, Xu J & Langkilde AM. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology 2017 5 864-876. (https://doi.org/10.1016/S2213-8587(17)30308-X)